# To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

> **NCT01829347** · PHASE3 · TERMINATED · sponsor: **Vital Therapies, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Severe Acute Alcoholic Hepatitis

## Interventions

- **BIOLOGICAL:** ELAD
- **OTHER:** Standard of Care treatment

## Key facts

- **NCT ID:** NCT01829347
- **Lead sponsor:** Vital Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2015-10
- **Final completion:** 2018-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Due to results from the VTI-208 study, the ELAD plan is being re-evaluated.
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829347, "To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01829347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*